Cargando…
Patient and Caregiver Preferences for First-Line Treatments of Metastatic Non-Small Cell Lung Cancer: A Discrete Choice Experiment
PURPOSE: The approval of immune checkpoint inhibitors for metastatic non-small-cell lung carcinomas (mNSCLC) treatment has presented more care options. Therefore, it is important to identify the benefit-risk trade-offs patients and caregivers are willing to make among potential treatment options. Th...
Autores principales: | Yong, Candice, Cambron-Mellott, M Janelle, Seal, Brian, Will, Oliver, Maculaitis, Martine C, Clapp, Kelly, Mulvihill, Emily, Cotarla, Ion, Mehra, Ranee |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8769053/ https://www.ncbi.nlm.nih.gov/pubmed/35068928 http://dx.doi.org/10.2147/PPA.S338840 |
Ejemplares similares
-
Patient and Neurologist Preferences in the United States for Relapsing-Remitting Multiple Sclerosis Treatments: Findings from a Discrete Choice Experiment
por: Kumar, Jinender, et al.
Publicado: (2021) -
Adult Patient Preferences for Long-Acting ADHD Treatments: A Discrete Choice Experiment
por: Cambron-Mellott, M Janelle, et al.
Publicado: (2021) -
Oncologist and Patient Preferences for Attributes of CDK4/6 Inhibitor Regimens for the Treatment of Advanced/Metastatic HR Positive/HER2 Negative Breast Cancer: Discrete Choice Experiment and Best–Worst Scaling
por: Maculaitis, Martine C, et al.
Publicado: (2020) -
Patient Preferences for Anti-Vascular Endothelial Growth Factor Treatment for Wet Age-Related Macular Degeneration in Japan: A Discrete Choice Experiment
por: Joko, Takeshi, et al.
Publicado: (2020) -
Patient, Oncologist, and Payer Preferences for Adjuvant Endocrine Therapy and CDK4/6 Inhibitor Regimens in Early-Stage Breast Cancer: A Discrete Choice Experiment
por: Beusterien, Kathleen, et al.
Publicado: (2021)